Peter Beck's Neutron Rocket Could Slip to 2027. Here's How Much the Delay Actually Matters.

Rocket Lab’s Neutron medium-lift rocket launch is likely delayed from a 2026 target to 2027 after a Stage 1 main propellant tank ruptured during a January hydrostatic pressure test. Management says the company will still roll Neutron to the launch pad by Q4, but completing additional ground tests is pushing the end-year window shorter. Rocket Lab reiterated an expected adjusted EBITDA inflection to positive once Neutron begins flying, while shares are noted as down 54% from the peak ahead of the revised timeline.

Analysis

The near-term read-through is less about launch optics and more about duration risk: every quarter of slippage pushes out the first credible step-up in gross profit mix, so the stock’s multiple is now hostage to cash burn rather than platform optionality. If Neutron is the main bridge to EBITDA positivity, then a 2027 reset means the market must underwrite at least one more year of “pre-inflection” losses, which typically compresses EV/revenue multiples for long-duration aerospace names even when the underlying thesis remains intact.

The second-order winner is the incumbent launch ecosystem, especially SpaceX economically and any large primes that can absorb delayed government/defense launch spend without execution risk. For RKLB, the sharper risk is financing: the longer the gap to meaningful medium-lift revenue, the more any operational hiccup in the space systems business matters because it has to fund development runway. That makes this a balance-sheet and cadence story over the next 6-12 months, not a “launch date” story.

Contrarian view: the market may already be discounting a 2027 first flight, so the real signal will be whether the company can hit pad milestones and avoid another schedule reset. If management can show recurring ground-test progress and preserve cash, the stock could bottom before the headline launch. The thesis is falsified by any further slip beyond 2027, evidence of rising cash burn without offsetting contract growth, or a financing event that shifts dilution risk forward.

Key Decisions for Investors

• Avoid adding to RKLB ahead of the next milestone window; treat any bounce on launch-roadmap rhetoric as a sale, with a tactical short only if the stock re-rates on thin volume and fails to hold post-earnings support.
• If long RKLB structurally, hedge with out-of-the-money puts into the next 1-3 month catalyst window; the cleanest risk is another schedule reset or disclosure that pushes EBITDA breakeven further out.
• Pair trade idea: long XAR (aerospace/defense exposure) vs short RKLB for 3-6 months to isolate execution risk in the launch name while keeping sector exposure neutral.
• Watch for any equity or convertible financing by RKLB over the next 6-12 months; that would be a stronger short signal than the launch delay itself because it confirms the market is funding development, not just deferring revenue.
• If RKLB can report consecutive test-milestone progress and stable cash burn, consider covering shorts rather than pressing them; the upside case is a de-risking re-rating, not near-term launch revenue.